Paulson, K. G.
Voillet, V.
McAfee, M. S.
Hunter, D. S.
Wagener, F. D.
Perdicchio, M.
Valente, W. J. http://orcid.org/0000-0002-9330-944X
Koelle, S. J.
Church, C. D.
Vandeven, N.
Thomas, H.
Colunga, A. G.
Iyer, J. G.
Yee, C.
Kulikauskas, R.
Koelle, D. M. http://orcid.org/0000-0003-1255-9023
Pierce, R. H.
Bielas, J. H.
Greenberg, P. D.
Bhatia, S.
Gottardo, R. http://orcid.org/0000-0002-3867-0232
Nghiem, P. http://orcid.org/0000-0003-2784-963X
Chapuis, A. G.
Article History
Received: 11 May 2018
Accepted: 15 August 2018
First Online: 24 September 2018
Competing Interests
: A.G. Chapuis has received support from Juno therapeutics. P.D.G. has received support and has ownership interest in Juno Therapeutics, Immune Design, and Innate Pharma. P.N. has received consulting fees from EMD Serono, Pfizer, Merck Sharpe and Dohne, Amgen, Incyte, Takeda, Mallinckrodt and research support from EMD Serono and Bristol-Meyers Squibb. A.G.C., M.S.M., D.M.K., K.G.P., C.D.C., and P.N. and their institutions have intellectual property related to T cell receptors recognizing Merkel cell polyomavirus. S.B. has received advisory board honoraria from Genentech and EMD-Serono; his institution (University of Washington) has received research funding from EMD-Serono, Merck, BMS, Oncosec, and Immune Design. A.G. Chapuis and K.G.P. have received reagents from 10X genomics. R.G. received consulting fees from Juno Therapeutics. The authors declare no other competing interests.